Dr Srour on the Phase 1 TRAVERSE Study of ALLO-316 in Metastatic Clear Cell RCC
Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
United States Samera Srour Department Of Stem Cell Transplantation Division Of Cancer Medicine University Of Texas Md Anderson Cancer Center Stem Cell Transplantation
Source: onclive.com